Search Results

CDR-Life Inc. today announced the initiation of enrollment for the Phase 1 trial of CDR404, its lead program in development as a precision immunotherapy for solid tumors.

CDR-Life Inc. today announced an expansion of its pipeline of novel T cell engagers (TCE) with the addition of CDR813 and CDR505.

CDR-Life Inc. today announced that Chief Medical Officer Swethajit Biswas, MD, FRCP, will co-lead a seminar at the 6th Annual Cell Engager Summit, occurring May 21-23 in Boston.

Dassault Systèmes announced it collaborated with CDR-Life, a Swiss biotherapeutics company, to accelerate CDR-Life’s development of next-generation highly tumor-selective immunotherapies using CDR-Life’s proprietary M-gager® platform.

CDR-Life Inc., in the run-up to initiation of its first Phase 1 clinical trial, presented two posters for CDR404, a first-of-its-kind, antibody-based, bivalent & bispecific MAGE-A4 T-cell engager (TCE) targeting MAGE-A4, an intracellular cancer protein with expression in several frequent and difficult to treat solid tumors, at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting.

CDR-Life Inc. presented findings on tumor target expression and precise patient selection for the upcoming Phase 1 trial of CDR404, a first-of-its-kind bispecific and bivalent antibody fragment-based T-cell engager targeting MAGE-A4, an intracellular protein which is presented on HLA-A*02:01 on the surface of cancer cells, at the ESMO Congress 2023, occurring October 20-24 in Madrid, Spain.